

## FDA clears Covidien's latest Nellcor continuous respiratory monitor

Mass Device

Covidien wins FDA clearance for its Nellcor Bedside SpO<sub>2</sub> patient monitoring system with continuous monitoring.



Medical device maker [Covidien](#) [1] (NYSE:[COV](#) [2]) touted FDA clearance for the latest in its line of Nellcor patient monitors, the Bedside SpO<sub>2</sub>.

The device continuously monitors SpO<sub>2</sub> and pulse rate for adult, pediatric and neonatal patients, providing access to comprehensive respiratory trends and subtle variations.

"Healthcare professionals on the general care floor, and in other lower-acuity areas of the hospital, need critical patient information at their fingertips so they can respond quickly to health threats," Covidien respiratory & monitoring solutions president Robert White said in [prepared remarks](#) [3]. "By giving them ready access to a patient's respiratory history, the system allows them to focus on delivering efficient, high-quality care, not gathering and managing data."

### Source URL (retrieved on 01/29/2015 - 9:54pm):

<http://www.mdtmag.com/news/2012/07/fda-clears-covidien-latest-nellcor-continuous-respiratory-monitor>

### Links:

[1] <http://www.massdevice.com/company/covidien>

[2] <http://www.google.com/finance?q=cov>

[3] <http://www.businesswire.com/news/home/20120730005150/en/Covidien-Announces-FDA-510-Clearance-Nellcor%E2%84%A2-Bedside>